Aquaporin-1 CRISPR/Cas9 gene therapy (University of Bristol)

N/A

Report date: 2025/09/29 17:48:54

Base Information

Drug NameAquaporin-1 CRISPR/Cas9 gene therapy (University of Bristol)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionAquaporin-1 inhibitors
TargetsAquaporin-1
Therapy Area/IndicationsGlaucoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Bristol
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Bristol
Inactive CompaniesN/A
Active IndicationsGlaucoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A